AUG 12, 2026 · JOURNAL ARTICLE
The course of platinum-based chemotherapy is associated with the risk of hematological complications during poly(ADP-ribose) polymerase (PARP) inhibitor therapy in patients with ovarian cancer
Pharmacological Reports
Retrospective single-centre analysis identifying associations between chemotherapy-induced parameters and PARP inhibitor toxicity, but lacks prospective validation, external cohort confirmation, and actionable clinical thresholds for practice change.
Reported
Sample size130
Niraparib cohort49
Olaparib cohort81